Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

K. Ina Ly, Bella Vakulenko-Lagun, Kyrre E. Emblem, Yangming Ou, Xiao Da, Rebecca Betensky, Jayashree Kalpathy-Cramer, Dan G. Duda, Rakesh K. Jain, Andrew S. Chi, Scott R. Plotkin, Tracy T. Batchelor, Gregory Sorensen, Bruce R. Rosen, Elizabeth R. Gerstner

Research output: Contribution to journalArticle

Abstract

Functional MRI may identify critical windows of opportunity for drug delivery and distinguish between early treatment responders and non-responders. Using diffusion-weighted, dynamic contrast-enhanced, and dynamic susceptibility contrast MRI, as well as pro-angiogenic and pro-inflammatory blood markers, we prospectively studied the physiologic tumor-related changes in fourteen newly diagnosed glioblastoma patients during standard therapy. 153 MRI scans and blood collection were performed before chemoradiation (baseline), weekly during chemoradiation (week 1–6), monthly before each cycle of adjuvant temozolomide (pre-C1-C6), and after cycle 6. The apparent diffusion coefficient, volume transfer coefficient (Ktrans), and relative cerebral blood volume (rCBV) and flow (rCBF) were calculated within the tumor and edema regions and compared to baseline. Cox regression analysis was used to assess the effect of clinical variables, imaging, and blood markers on progression-free (PFS) and overall survival (OS). After controlling for additional covariates, high baseline rCBV and rCBF within the edema region were associated with worse PFS (microvessel rCBF: HR = 7.849, p = 0.044; panvessel rCBV: HR = 3.763, p = 0.032; panvessel rCBF: HR = 3.984; p = 0.049). The same applied to high week 5 and pre-C1 Ktrans within the tumor region (week 5 Ktrans: HR = 1.038, p = 0.003; pre-C1 Ktrans: HR = 1.029, p = 0.004). Elevated week 6 VEGF levels were associated with worse OS (HR = 1.034; p = 0.004). Our findings suggest a role for rCBV and rCBF at baseline and Ktrans and VEGF levels during treatment as markers of response. Functional imaging changes can differ substantially between tumor and edema regions, highlighting the variable biologic and vascular state of tumor microenvironment during therapy.

Original languageEnglish (US)
Article number17062
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

temozolomide
Cerebrovascular Circulation
Tumor Microenvironment
Glioblastoma
Magnetic Resonance Imaging
Edema
Vascular Endothelial Growth Factor A
Neoplasms
Survival
Therapeutics
Microvessels
Blood Vessels
Regression Analysis
Cerebral Blood Volume
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. / Ina Ly, K.; Vakulenko-Lagun, Bella; Emblem, Kyrre E.; Ou, Yangming; Da, Xiao; Betensky, Rebecca; Kalpathy-Cramer, Jayashree; Duda, Dan G.; Jain, Rakesh K.; Chi, Andrew S.; Plotkin, Scott R.; Batchelor, Tracy T.; Sorensen, Gregory; Rosen, Bruce R.; Gerstner, Elizabeth R.

In: Scientific Reports, Vol. 8, No. 1, 17062, 01.12.2018.

Research output: Contribution to journalArticle

Ina Ly, K, Vakulenko-Lagun, B, Emblem, KE, Ou, Y, Da, X, Betensky, R, Kalpathy-Cramer, J, Duda, DG, Jain, RK, Chi, AS, Plotkin, SR, Batchelor, TT, Sorensen, G, Rosen, BR & Gerstner, ER 2018, 'Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI', Scientific Reports, vol. 8, no. 1, 17062. https://doi.org/10.1038/s41598-018-34820-x
Ina Ly, K. ; Vakulenko-Lagun, Bella ; Emblem, Kyrre E. ; Ou, Yangming ; Da, Xiao ; Betensky, Rebecca ; Kalpathy-Cramer, Jayashree ; Duda, Dan G. ; Jain, Rakesh K. ; Chi, Andrew S. ; Plotkin, Scott R. ; Batchelor, Tracy T. ; Sorensen, Gregory ; Rosen, Bruce R. ; Gerstner, Elizabeth R. / Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{d3f628ed1f9d4675b8bdd76e87c79dc0,
title = "Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI",
abstract = "Functional MRI may identify critical windows of opportunity for drug delivery and distinguish between early treatment responders and non-responders. Using diffusion-weighted, dynamic contrast-enhanced, and dynamic susceptibility contrast MRI, as well as pro-angiogenic and pro-inflammatory blood markers, we prospectively studied the physiologic tumor-related changes in fourteen newly diagnosed glioblastoma patients during standard therapy. 153 MRI scans and blood collection were performed before chemoradiation (baseline), weekly during chemoradiation (week 1–6), monthly before each cycle of adjuvant temozolomide (pre-C1-C6), and after cycle 6. The apparent diffusion coefficient, volume transfer coefficient (Ktrans), and relative cerebral blood volume (rCBV) and flow (rCBF) were calculated within the tumor and edema regions and compared to baseline. Cox regression analysis was used to assess the effect of clinical variables, imaging, and blood markers on progression-free (PFS) and overall survival (OS). After controlling for additional covariates, high baseline rCBV and rCBF within the edema region were associated with worse PFS (microvessel rCBF: HR = 7.849, p = 0.044; panvessel rCBV: HR = 3.763, p = 0.032; panvessel rCBF: HR = 3.984; p = 0.049). The same applied to high week 5 and pre-C1 Ktrans within the tumor region (week 5 Ktrans: HR = 1.038, p = 0.003; pre-C1 Ktrans: HR = 1.029, p = 0.004). Elevated week 6 VEGF levels were associated with worse OS (HR = 1.034; p = 0.004). Our findings suggest a role for rCBV and rCBF at baseline and Ktrans and VEGF levels during treatment as markers of response. Functional imaging changes can differ substantially between tumor and edema regions, highlighting the variable biologic and vascular state of tumor microenvironment during therapy.",
author = "{Ina Ly}, K. and Bella Vakulenko-Lagun and Emblem, {Kyrre E.} and Yangming Ou and Xiao Da and Rebecca Betensky and Jayashree Kalpathy-Cramer and Duda, {Dan G.} and Jain, {Rakesh K.} and Chi, {Andrew S.} and Plotkin, {Scott R.} and Batchelor, {Tracy T.} and Gregory Sorensen and Rosen, {Bruce R.} and Gerstner, {Elizabeth R.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-34820-x",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

AU - Ina Ly, K.

AU - Vakulenko-Lagun, Bella

AU - Emblem, Kyrre E.

AU - Ou, Yangming

AU - Da, Xiao

AU - Betensky, Rebecca

AU - Kalpathy-Cramer, Jayashree

AU - Duda, Dan G.

AU - Jain, Rakesh K.

AU - Chi, Andrew S.

AU - Plotkin, Scott R.

AU - Batchelor, Tracy T.

AU - Sorensen, Gregory

AU - Rosen, Bruce R.

AU - Gerstner, Elizabeth R.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Functional MRI may identify critical windows of opportunity for drug delivery and distinguish between early treatment responders and non-responders. Using diffusion-weighted, dynamic contrast-enhanced, and dynamic susceptibility contrast MRI, as well as pro-angiogenic and pro-inflammatory blood markers, we prospectively studied the physiologic tumor-related changes in fourteen newly diagnosed glioblastoma patients during standard therapy. 153 MRI scans and blood collection were performed before chemoradiation (baseline), weekly during chemoradiation (week 1–6), monthly before each cycle of adjuvant temozolomide (pre-C1-C6), and after cycle 6. The apparent diffusion coefficient, volume transfer coefficient (Ktrans), and relative cerebral blood volume (rCBV) and flow (rCBF) were calculated within the tumor and edema regions and compared to baseline. Cox regression analysis was used to assess the effect of clinical variables, imaging, and blood markers on progression-free (PFS) and overall survival (OS). After controlling for additional covariates, high baseline rCBV and rCBF within the edema region were associated with worse PFS (microvessel rCBF: HR = 7.849, p = 0.044; panvessel rCBV: HR = 3.763, p = 0.032; panvessel rCBF: HR = 3.984; p = 0.049). The same applied to high week 5 and pre-C1 Ktrans within the tumor region (week 5 Ktrans: HR = 1.038, p = 0.003; pre-C1 Ktrans: HR = 1.029, p = 0.004). Elevated week 6 VEGF levels were associated with worse OS (HR = 1.034; p = 0.004). Our findings suggest a role for rCBV and rCBF at baseline and Ktrans and VEGF levels during treatment as markers of response. Functional imaging changes can differ substantially between tumor and edema regions, highlighting the variable biologic and vascular state of tumor microenvironment during therapy.

AB - Functional MRI may identify critical windows of opportunity for drug delivery and distinguish between early treatment responders and non-responders. Using diffusion-weighted, dynamic contrast-enhanced, and dynamic susceptibility contrast MRI, as well as pro-angiogenic and pro-inflammatory blood markers, we prospectively studied the physiologic tumor-related changes in fourteen newly diagnosed glioblastoma patients during standard therapy. 153 MRI scans and blood collection were performed before chemoradiation (baseline), weekly during chemoradiation (week 1–6), monthly before each cycle of adjuvant temozolomide (pre-C1-C6), and after cycle 6. The apparent diffusion coefficient, volume transfer coefficient (Ktrans), and relative cerebral blood volume (rCBV) and flow (rCBF) were calculated within the tumor and edema regions and compared to baseline. Cox regression analysis was used to assess the effect of clinical variables, imaging, and blood markers on progression-free (PFS) and overall survival (OS). After controlling for additional covariates, high baseline rCBV and rCBF within the edema region were associated with worse PFS (microvessel rCBF: HR = 7.849, p = 0.044; panvessel rCBV: HR = 3.763, p = 0.032; panvessel rCBF: HR = 3.984; p = 0.049). The same applied to high week 5 and pre-C1 Ktrans within the tumor region (week 5 Ktrans: HR = 1.038, p = 0.003; pre-C1 Ktrans: HR = 1.029, p = 0.004). Elevated week 6 VEGF levels were associated with worse OS (HR = 1.034; p = 0.004). Our findings suggest a role for rCBV and rCBF at baseline and Ktrans and VEGF levels during treatment as markers of response. Functional imaging changes can differ substantially between tumor and edema regions, highlighting the variable biologic and vascular state of tumor microenvironment during therapy.

UR - http://www.scopus.com/inward/record.url?scp=85056801911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056801911&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-34820-x

DO - 10.1038/s41598-018-34820-x

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 17062

ER -